To delve deeper into the potential role of CCL24 in antiangiogenic therapy and chemoresistance, we expanded our study to include 92 patients with CRC who received chemotherapy or chemotherapy plus antiangiogenic therapy during their treatment. The gene discussed is CCL24; the disease is colorectal carcinoma.